Therapeutic drug monitoring

Use of biologic therapies such as monoclonal antibodies and fusion proteins have changed the clinical course of many autoimmune conditions such as inflammatory bowel disease (IBD) psoriasis and rheumatoid arthritis1. Despite the beneficial responses observed in patients undergoing such therapies with biologics, primary non-response and secondary loss of response (SLR) to these treatments is common, with SLR occurring in approximately 70% of patients1.

Treatment with biologics is expensive and with a limited choice of agents suitable for use in IBD patients, monitoring of the response is key to preventing such loss of response. TDM involves the assessment of drug levels within an individual together with the detection of antibodies against the drug. TDM is typically managed in 2 ways: Proactive and Reactive testing.

Proactive TDM is used in patients demonstrating a response to the specific therapy as a tool to optimise the therapy, potentially to prevent periodic disease flares and loss of response; it helps minimise overexposure to the drug while maximising the patient response. Reactive TDM is performed in patients demonstrating a loss of response, to guide decision making2.

The use of either Proactive or Reactive TDM has been shown to be a cost-effective strategy to reduce the high cost associated with management of chronic inflammatory diseases.

Publications
1. Silva-Ferreira F, Afonso J, Pinto-Lopes P, Magro F. A Systematic Review on Infliximab and Adalimumab Drug Monitoring: Levels, Clinical Outcomes and Assays. Inflamm Bowel Dis. 2016;22(9):2289-2301. doi:10.1097/MIB.0000000000000855

2. Roblin X, Riviere P, Flamant M, et al. Proactive Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018;24(9):1904-1909. doi:10.1093/ibd/izy069

Therapeutic Drug Monitoring Solutions

Portfolio Certification Clinical Area Product Type RUO/IVD
LISA-TRACKER anti-Trastuzumab

CE Marked

Manual IVD
i-Tracker Infliximab

CE Marked

Automated IVD
i-Tracker anti-Infliximab

CE Marked

Automated IVD
LISA-TRACKER Duo Infliximab

CE Marked

Manual IVD
LISA-TRACKER Infliximab

CE Marked

Manual IVD
LISA-TRACKER anti-Infliximab

CE Marked

Manual IVD
i-Tracker Adalimumab

CE Marked

Automated IVD
i-Tracker anti-Adalimumab

CE Marked

Automated IVD
LISA-TRACKER Duo Adalimumab

CE Marked

Manual IVD
LISA-TRACKER Adalimumab

CE Marked

Manual IVD
LISA-TRACKER anti-Adalimumab

CE Marked

Manual IVD
LISA-TRACKER Trastuzumab

CE Marked

Manual IVD
LISA-TRACKER Duo Trastuzumab

CE Marked

Manual IVD
LISA-TRACKER anti-Vedolizumab

CE Marked

Manual IVD
LISA-TRACKER Vedolizumab

CE Marked

Manual IVD
LISA-TRACKER Duo Vedolizumab

CE Marked

Manual IVD
LISA-TRACKER Ustekinumab

CE Marked

Manual IVD
LISA-TRACKER anti-Ustekinumab

CE Marked

Manual IVD
LISA-TRACKER Duo Ustekinumab

CE Marked

Manual IVD
LISA-TRACKER anti-Tocilizumab

CE Marked

Manual IVD
LISA-TRACKER Tocilizumab

CE Marked

Manual IVD
LISA-TRACKER Duo Tocilizumab

CE Marked

Manual IVD
LISA-TRACKER anti-Secukinumab

CE Marked

Manual IVD
LISA-TRACKER Secukinumab

CE Marked

Manual IVD
LISA-TRACKER anti-Rituximab

CE Marked

Manual IVD
LISA-TRACKER Rituximab

CE Marked

Manual IVD
LISA-TRACKER Golimumab

CE Marked

Manual IVD
LISA-TRACKER anti-Golimumab

CE Marked

Manual IVD
LISA-TRACKER Duo Golimumab

CE Marked

Manual IVD
LISA-TRACKER anti-Etanercept

CE Marked

Manual IVD
LISA-TRACKER Etanercept

CE Marked

Manual IVD
LISA-TRACKER Duo Etanercept

CE Marked

Manual IVD
LISA-TRACKER anti-Certolizumab

CE Marked

Manual IVD
LISA-TRACKER Duo Certolizumab

CE Marked

Manual IVD
LISA-TRACKER anti-Bevacizumab

CE Marked

Manual IVD
LISA-TRACKER Bevacizumab

CE Marked

Manual IVD
LISA-TRACKER Duo Bevacizumab

CE Marked

Manual IVD

Search products

Keyword Search

You can use the keyword search to get results based on specific words or phrases relating to your chosen product

Need more information? Get in touch

Fill in the boxes below to get in contact